Show simple item record

 
dc.contributorVall d'Hebron Barcelona Hospital Campus
dc.contributor.authorStatz-Geary, Kurt
dc.contributor.authorElliott, Andrew
dc.contributor.authorBialick, Steven
dc.contributor.authorOberley, Matthew
dc.contributor.authorSerrano, Cesar
dc.contributor.authorvon Mehren, Margaret
dc.date.accessioned2025-09-05T12:16:16Z
dc.date.available2025-09-05T12:16:16Z
dc.date.issued2025-06-12
dc.identifier.citationStatz-Geary K, Elliott A, Bialick S, Serrano C, von Mehren M, Oberley M, et al. DNA Damage Repair Pathway Alterations and Immune Landscape Differences in Pediatric/Adolescent, Young Adult (AYA) and Adult Sarcomas. Cancers (Basel). 2025 Jun 12;17(12):1962.
dc.identifier.issn2072-6694
dc.identifier.urihttp://hdl.handle.net/11351/13619
dc.descriptionDNA damage response; Precision medicine; Sarcoma
dc.description.abstractBackground: DNA damage response (DDR) pathway alterations contribute to genomic instability and malignant progression in several cancers. Methods: We retrospectively reviewed molecular profiles from 5309 sarcoma patient samples, including 746 from pediatric/adolescent and young adults (ped/AYA), encompassing 38 histologic subtypes. The gene expression profiles were further analyzed for immunotherapy-related biomarker associations, including analysis of the T cell-inflamed score. Results: Pathogenic/likely pathogenic DDR alterations were detected in 15.9% (N = 842) of samples overall and 9.25% (N = 69) of Ped/AYA tumors, with mutations occurring most frequently in ATRX (10.1%). Shorter overall survival was observed for patients with DDR-alterations compared to those with DDR-wildtype tumors (Hazard Ratio = 1.172, 95% CI: 1.068-1.287; p < 0.001). In many subtypes, DDR-mutated tumors were found to have increased rates of immune markers, including PD-L1+, dMMR/MSI-high, and TMB. Conclusions: Our study of somatic DDR-pathway mutations provides a better understanding of the molecular associations across sarcoma subtypes that may aid in developing future prognostic and therapeutic options for these rare cancers.
dc.language.isoeng
dc.publisherMDPI
dc.relation.ispartofseriesCancers;17(12)
dc.rightsAttribution 4.0 International
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.sourceScientia
dc.subjectADN - Dany
dc.subjectAnomalies cromosòmiques
dc.subjectCàncer - Aspectes genètics
dc.subjectSarcoma - Aspectes genètics
dc.subject.meshDNA Damage
dc.subject.meshSarcoma
dc.subject.mesh/genetics
dc.subject.meshNeoplasms
dc.subject.meshMutation
dc.titleDNA Damage Repair Pathway Alterations and Immune Landscape Differences in Pediatric/Adolescent, Young Adult (AYA) and Adult Sarcomas
dc.typeinfo:eu-repo/semantics/article
dc.identifier.doi10.3390/cancers17121962
dc.subject.decsdaño del ADN
dc.subject.decssarcoma
dc.subject.decs/genética
dc.subject.decsneoplasias
dc.subject.decsmutación
dc.relation.publishversionhttps://doi.org/10.3390/cancers17121962
dc.type.versioninfo:eu-repo/semantics/publishedVersion
dc.audienceProfessionals
dc.contributor.organismesInstitut Català de la Salut
dc.contributor.authoraffiliation[Statz-Geary K] Miller School of Medicine/Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL, USA. Jackson Memorial Hospital, Miami, FL, USA. [Elliott A, Oberley M] Caris Life Sciences, Phoenix, AZ, USA. [Bialick S] Miller School of Medicine/Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL, USA. [Serrano C] Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. [von Mehren M] Fox Chase Cancer Center, Philadelphia, PA, USA
dc.identifier.pmid40563612
dc.identifier.wos001515478500001
dc.relation.projectidinfo:eu-repo/grantAgreement/ES/PEICTI2021-2023/PI22%2F00720
dc.rights.accessrightsinfo:eu-repo/semantics/openAccess


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record